Humacyte (HUMA) Total Liabilities (2020 - 2026)
Humacyte (HUMA) posted quarterly Total Liabilities of $98.9 million for Q1 2026, down 21.8% year-over-year from $126.5 million in Q1 2025, and down 12.65% quarter-over-quarter from $113.3 million in Q4 2025.
Humacyte (HUMA) Total Liabilities (2020 - 2026) Analysis & Trends
Humacyte (HUMA) has reported Total Liabilities for 7 consecutive years, with $98.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities fell 21.8% year-over-year to $98.9 million; the TTM figure through Mar 2026 stood at $98.9 million (down 21.8% YoY), while the FY2025 annual figure was $113.3 million, down 40.56% from the prior year.
- Total Liabilities fell to $98.9 million in Q1 2026 per HUMA's latest filing, from $113.3 million in the prior quarter.
- Across five years, Total Liabilities topped out at $190.5 million in Q4 2024 and bottomed at $87.4 million in Q4 2022.
- Historically, Total Liabilities has averaged $125.6 million across 5 years, with a median of $113.3 million in 2025.
- On a YoY basis, Total Liabilities climbed as much as 830.5% in 2022 and fell as far as 52.73% in 2022.
- Humacyte's Total Liabilities stood at $87.4 million in 2022, then soared by 31.25% to $114.7 million in 2023, then surged by 66.15% to $190.5 million in 2024, then tumbled by 40.56% to $113.3 million in 2025, then slipped by 12.65% to $98.9 million in 2026.
- Business Quant data shows HUMA's Total Liabilities at $98.9 million in Q1 2026, $113.3 million in Q4 2025, and $96.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | Humacyte | 158.12 Mn | 158.12 Mn | -825,000.00 | 106.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 106.83 Mn |
| Mar 31, 2026 | 98.93 Mn |
| Dec 31, 2025 | 113.26 Mn |
| Sep 30, 2025 | 96.26 Mn |
| Jun 30, 2025 | 134.74 Mn |
| Mar 31, 2025 | 126.51 Mn |
| Dec 31, 2024 | 190.54 Mn |
| Sep 30, 2024 | 178.49 Mn |
| Jun 30, 2024 | 166.57 Mn |
| Mar 31, 2024 | 135.31 Mn |
| Dec 31, 2023 | 114.68 Mn |
| Sep 30, 2023 | 112.39 Mn |
| Jun 30, 2023 | 106.99 Mn |
| Mar 31, 2023 | 101.09 Mn |
| Dec 31, 2022 | 87.37 Mn |
| Sep 30, 2022 | 107.55 Mn |
| Jun 30, 2022 | 104.11 Mn |
| Mar 31, 2022 | 160.58 Mn |
| Dec 31, 2021 | 164.36 Mn |
| Sep 30, 2021 | 227.50 Mn |